Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN-002 in low-risk basal cell carcinoma
ACTRN12619001298101Phase 2Not yet recruiting
- Sponsor
- Ascend Biopharmaceuticals Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gusacitinib and fluorouracil in basal cell carcinoma (BCC) and Basal cell nevus syndrome (BCNS) (7 arms), sponsored by Ascend Biopharmaceuticals Ltd. Primary endpoints: Safety and tolerability of ASN-002 with 5-fluorouracil and Safety and tolerability of ASN-002 in multiple untreated BCC lesions. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
gusacitinibfluorouracil
03
Conditions
basal cell carcinoma (BCC)Basal cell nevus syndrome (BCNS)
Beyond the preview
Go deeper on ACTRN12619001298101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001298101.